Adult Liver Transplant Candidate Evaluation: What the New AASLD/AST Guideline Changes

Introduction and Context

Liver transplantation is one of the most effective life-saving treatments in modern medicine, but it is also one of the most resource-limited. Because donor organs are scarce, the central question is not simply who might benefit from transplant, but who is most likely to benefit enough to justify allocation of a national resource. The 2025 AASLD/AST Practice Guideline on adult liver transplantation candidate evaluation was issued to provide a modern, structured framework for this decision-making process.

This guideline matters because the candidate-evaluation process has become more complex. Adult liver transplant recipients are older, have more comorbidities, and are more likely to present with multifactorial illness, including metabolic dysfunction-associated steatotic liver disease, alcohol-associated liver disease, viral hepatitis, and hepatocellular carcinoma. At the same time, transplant systems must balance benefit, justice, and equity, while avoiding both over-restriction and inappropriate listing. The updated guideline aims to standardize evaluation, reduce unwarranted variation across centers, and help teams identify both medical indications and barriers to successful outcomes.

A key message from the expert panel is that transplant evaluation is not merely a box-checking exercise. It is a careful process to determine whether the patient has a clear indication, whether risks are modifiable, and whether there is a realistic pathway to good post-transplant survival and quality of life.

Why the Guideline Was Updated

The previous AASLD guidance dates back to 2005. Since then, the evidence base and transplant population have changed substantially. Several developments drove the update:

• Broader use of liver transplantation for conditions beyond classic cirrhosis, including selected cancers and acute-on-chronic liver failure.
• Growing recognition of frailty, sarcopenia, and psychosocial determinants of outcome.
• Increasing importance of alcohol use disorder treatment engagement and relapse-risk assessment.
• More refined cardiopulmonary assessment strategies for candidates with advanced liver disease.
• Greater attention to equity, disability, mental health, and socioeconomic barriers that may influence transplant access.

The writing group reviewed the literature over 24 months and rated evidence using the Oxford Centre for Evidence-Based Medicine framework. Recommendations were then classified by evidence level, risk–benefit balance, and patient preferences.

New Guideline Highlights

The updated guideline strengthens several principles that now define contemporary candidate evaluation:

Theme	Current emphasis
Equity	Evaluation should be fair, transparent, and aimed at equitable access across sites and populations.
Multidisciplinary care	Transplant candidacy should be assessed by hepatology, surgery, anesthesia, psychology/psychiatry, social work, and when needed cardiology, addiction medicine, oncology, and other specialists.
Benefit-based selection	Listing should be reserved for patients with a clear indication and a reasonable expectation of survival and functional benefit.
Risk modification	Potentially reversible barriers should be identified early and addressed before final listing decisions.
Psychosocial readiness	Adherence, support systems, substance use, and mental health are not secondary issues; they are core transplant variables.

The guideline also reinforces that evaluation should produce a practical transplant plan, not only a yes/no decision. That means defining the indication, anticipated urgency, modifiable risks, and post-transplant support needs.

Core Recommendations by Topic

1) Indication and Timing

The first step is to confirm a valid transplant indication. In general, the panel supports evaluation for adults with decompensated cirrhosis, acute liver failure, selected hepatic malignancies, and other advanced liver diseases when transplant is expected to improve survival or quality of life.

The guideline emphasizes that timing should be individualized. Patients should not be referred too late, after frailty or multiorgan failure has become irreversible. At the same time, transplant should not be offered when predicted benefit is low or competing comorbidities dominate prognosis.

2) Medical Assessment

The medical evaluation should document liver disease severity, comorbid conditions, and operative risk. Core elements include:

• Assessment of liver disease etiology and stage.
• Review of prior decompensations such as ascites, encephalopathy, variceal bleeding, and jaundice.
• Laboratory and imaging studies for portal hypertension, liver anatomy, and cancer screening when indicated.
• Evaluation of kidney function, nutrition, frailty, and sarcopenia.
• Cardiovascular and pulmonary risk assessment tailored to age, diabetes, obesity, prior heart disease, and symptoms.

Frailty is highlighted as an important predictor of waitlist and post-transplant outcomes. The panel supports formal assessment rather than relying solely on clinical impression. Likewise, sarcopenia and malnutrition should be actively sought and treated.

3) Cardiopulmonary Evaluation

Cardiac disease remains a major source of perioperative risk. The guideline supports risk-based cardiac testing rather than a one-size-fits-all approach. Candidates with advanced age, diabetes, metabolic risk, symptoms, or known heart disease should undergo more detailed testing. Pulmonary hypertension, hepatopulmonary syndrome, and other liver-related cardiopulmonary disorders must also be assessed when clinically suspected.

The major principle is to identify prohibitive risk early, while avoiding unnecessary testing in low-risk patients.

4) Alcohol and Substance Use Assessment

The guideline reflects the field’s shift away from rigid, time-based sobriety rules toward a more nuanced, individualized approach. For alcohol-associated liver disease, duration of abstinence alone should not be the sole determinant of candidacy. Instead, the team should assess treatment engagement, insight, relapse risk, social support, prior treatment history, and ongoing monitoring plans.

This is one of the most important changes in practice philosophy. The committee acknowledges that a fixed abstinence duration may not predict outcomes as well as a structured psychosocial and addiction-medicine evaluation. Similar principles apply to other substance use disorders.

5) Psychosocial Evaluation

Psychosocial readiness is central to transplant success. The evaluation should address:

• Adherence to prior medical care.
• Understanding of transplant requirements and lifelong immunosuppression.
• Availability of a reliable caregiver or support network.
• Housing, transportation, and financial barriers.
• Mental health conditions such as depression, anxiety, psychosis, or cognitive impairment.
• History of trauma, intimate partner violence, or other social vulnerabilities when relevant.

Importantly, psychosocial findings should be used to identify needs and barriers, not to exclude patients without offering pathways to improvement. The guideline supports targeted interventions such as counseling, addiction treatment, social work support, and caregiver planning.

6) Malignancy Evaluation

Patients with hepatocellular carcinoma and other selected cancers require careful staging and tumor-specific selection criteria. The panel reinforces that transplant can be appropriate when tumor burden is within accepted bounds and there is no evidence of extrahepatic spread or uncontrolled progression. Candidates with cancer outside standard criteria should be reviewed in a multidisciplinary setting, often with oncology input.

The key issue is balancing oncologic benefit against recurrence risk.

7) Special Populations

The guideline addresses several groups that require individualized decisions:

• Older adults: chronological age alone should not exclude transplant, but physiologic reserve and comorbidity burden matter greatly.
• Patients with obesity and metabolic disease: obesity is not an automatic contraindication, but associated cardiometabolic risk must be assessed carefully.
• Patients with renal dysfunction: kidney injury may be reversible or irreversible; combined liver-kidney transplantation should be considered when appropriate.
• Patients with HIV, viral hepatitis, or other chronic infections: these are no longer automatic barriers when well controlled.
• Patients with mental illness: psychiatric diagnoses alone should not exclude candidacy if symptoms are treated and adherence is feasible.

Updated Recommendations and Key Changes Compared With Earlier Practice

A useful way to understand the new guideline is to compare its philosophy with older transplant-era approaches.

Area	Older practice patterns	2025 guideline direction
Alcohol-associated liver disease	Rigid sobriety rules often used	Individualized relapse-risk and treatment-engagement assessment
Psychosocial evaluation	Often variable across centers	Structured, multidisciplinary, and linked to interventions
Frailty	Sometimes underrecognized	Formal evaluation encouraged as a prognostic factor
Equity	Implicit objective	Explicit focus on fair access and national resource stewardship
Cardiopulmonary testing	Broad testing in many candidates	Risk-based testing and targeted specialist assessment

These updates reflect an important maturation in transplant medicine: candidacy is no longer defined only by liver severity, but by the whole patient’s capacity to benefit.

Expert Commentary and Areas of Controversy

The panel’s consensus is that liver transplant should be offered to selected adults with clear indications and realistic benefit. However, several areas remain debated.

First, there is ongoing tension between standardized rules and individualized assessment. Programs want consistency, but overstandardization can unfairly exclude patients whose social circumstances are modifiable. The guideline leans toward individualized review, especially for psychosocial and substance use questions.

Second, the role of sobriety duration continues to spark discussion. Some centers still value a fixed abstinence period as a marker of stability. The updated guidance suggests that this is too blunt a tool and may unfairly penalize patients with severe disease who would benefit from earlier evaluation.

Third, frailty and sarcopenia are increasingly important but not yet fully harmonized across centers. Different measurement tools exist, and thresholds vary. The guideline supports use of objective measures, while acknowledging that implementation remains uneven.

Finally, equity remains a major challenge. Even with a national organ allocation system, referral patterns, evaluation access, and listing decisions can differ by geography, insurance status, race, ethnicity, and language. The committee’s emphasis on justice is a reminder that good guidelines must also be operationalized fairly.

Practical Implications for Clinicians

For clinicians, the most important practical message is to refer early and evaluate comprehensively. A patient should not be sent for transplant only after repeated hospitalizations and irreversible decline. Early referral allows time to address malnutrition, cardiac risk, alcohol treatment, caregiver planning, and cancer staging.

A typical evaluation should answer five questions:

1. Is there a clear transplant indication?
2. Is the patient sick enough to benefit, but not so ill that benefit is unlikely?
3. Are there modifiable medical or psychosocial barriers?
4. Is there a realistic plan for surgery, recovery, and long-term follow-up?
5. Does transplant align with the patient’s goals and values?

Fictional vignette: John, a 58-year-old man with alcohol-associated cirrhosis, recurrent ascites, and two hospitalizations for encephalopathy, is referred for transplant evaluation. Under older practice models, he might have been denied immediately because he stopped drinking only four months ago. Under the updated framework, the team would assess his relapse risk, addiction treatment engagement, caregiver support, frailty, and cardiometabolic status. If barriers are modifiable and he has a reasonable chance of benefit, he may remain a candidate.

This approach is both more humane and more clinically grounded. It does not lower the bar for transplant; rather, it broadens the lens through which benefit is judged.

What This Means for Health Systems

The guideline has implications beyond individual patients. Transplant centers may need more standardized evaluation pathways, better access to addiction medicine and psychiatry, and more consistent frailty measurement. Referring clinicians should also recognize the value of early consultation, especially in patients with decompensated cirrhosis, hepatocellular carcinoma, or worsening renal function.

Because liver transplantation is a shared national resource, the success of the system depends on high-quality candidate selection. The new guideline attempts to ensure that scarcity is managed ethically, transparently, and with maximum medical benefit.

Conclusion

The updated AASLD/AST guideline reframes adult liver transplant evaluation as a structured, multidisciplinary process focused on benefit, equity, and realistic success. Its most important messages are straightforward: refer early, assess broadly, use objective risk tools where possible, and do not rely on outdated single-factor rules such as sobriety duration alone.

For clinicians, the guideline provides a practical template for decision-making. For patients, it offers a clearer and more equitable path to one of the most important therapies in advanced liver disease. For transplant programs, it reinforces that candidate evaluation must be both rigorous and fair.

References

1. Dove L, Chadha RM, Lai JC, et al. AASLD AST Practice Guideline on adult liver transplantation: Candidate evaluation. Hepatology. 2025;83(6):1609-1645. PMID: 41405234.
2. Martin P, DiMartini A, Feng S, Brown R Jr, Fallon M. Evaluation for liver transplantation in adults: 2013 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation. Hepatology. 2014;59(3):1144-1165.
3. Wiesner RH, McDiarmid SV, Kamath PS, et al. Selection criteria and exclusion criteria for liver transplantation. Hepatology. 1999;29(6):1851-1858.
4. Charlton M, Levitsky J, Aqel B, et al. International Liver Transplantation Society consensus statement on liver transplantation in adults with acute-on-chronic liver failure. Transplantation. 2020;104(11):2300-2309.
5. Durand F, Graziadei I, Renz JF, et al. Liver transplantation for alcohol-related liver disease. J Hepatol. 2023;78(6):1400-1417.